CorMedix IncNASDAQ:CRMD
- LAST PRICE9.5950
- TODAY'S CHANGE (%)-0.3550 (-3.5678%)
- Bid / Lots9.5900/ 7
- Ask / Lots9.6000/ 6
- Open / Previous Close9.9500 / 9.9500
- Day Range
- 52 Week Range
- Volume531,808
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRMD |
|---|---|---|
| 09:32 ET | 7686 | 10.04 |
| 09:33 ET | 2285 | 10.0021 |
| 09:35 ET | 2303 | 9.91 |
| 09:37 ET | 5593 | 10.015 |
| 09:39 ET | 2100 | 10.01 |
| 09:42 ET | 600 | 10.01 |
| 09:44 ET | 4902 | 9.91 |
| 09:46 ET | 3815 | 9.924 |
| 09:48 ET | 4272 | 9.95 |
| 09:50 ET | 2303 | 9.85 |
| 09:51 ET | 1673 | 9.87 |
| 09:55 ET | 2892 | 9.86 |
| 09:57 ET | 465 | 9.83 |
| 10:00 ET | 7359 | 9.76 |
| 10:02 ET | 28218 | 9.6687 |
| 10:04 ET | 41679 | 9.63 |
| 10:06 ET | 3198 | 9.67 |
| 10:08 ET | 6889 | 9.74 |
| 10:09 ET | 2550 | 9.7 |
| 10:11 ET | 3797 | 9.7 |
| 10:13 ET | 4591 | 9.6699 |
| 10:15 ET | 774 | 9.69 |
| 10:18 ET | 2830 | 9.65 |
| 10:20 ET | 412 | 9.67 |
| 10:22 ET | 1320 | 9.67 |
| 10:24 ET | 649 | 9.66 |
| 10:26 ET | 3100 | 9.6635 |
| 10:27 ET | 10429 | 9.7196 |
| 10:29 ET | 800 | 9.69 |
| 10:31 ET | 3149 | 9.69 |
| 10:33 ET | 486 | 9.68 |
| 10:36 ET | 900 | 9.69 |
| 10:38 ET | 27931 | 9.65 |
| 10:40 ET | 20095 | 9.59 |
| 10:42 ET | 13984 | 9.57 |
| 10:44 ET | 900 | 9.62 |
| 10:45 ET | 3050 | 9.615 |
| 10:47 ET | 3694 | 9.63 |
| 10:49 ET | 9390 | 9.5635 |
| 10:51 ET | 9618 | 9.6 |
| 10:54 ET | 6154 | 9.6 |
| 10:56 ET | 5792 | 9.64 |
| 10:58 ET | 8293 | 9.59 |
| 11:00 ET | 1846 | 9.64 |
| 11:02 ET | 2963 | 9.611 |
| 11:03 ET | 2979 | 9.67 |
| 11:05 ET | 6712 | 9.71 |
| 11:07 ET | 4875 | 9.68 |
| 11:09 ET | 10805 | 9.64 |
| 11:12 ET | 16936 | 9.59 |
| 11:14 ET | 21787 | 9.51 |
| 11:16 ET | 3643 | 9.6 |
| 11:18 ET | 2738 | 9.6063 |
| 11:20 ET | 9191 | 9.5694 |
| 11:21 ET | 4122 | 9.56 |
| 11:23 ET | 2937 | 9.5804 |
| 11:25 ET | 7580 | 9.5583 |
| 11:27 ET | 4973 | 9.59 |
| 11:30 ET | 3936 | 9.585 |
| 11:32 ET | 17402 | 9.57 |
| 11:34 ET | 11563 | 9.54 |
| 11:36 ET | 2857 | 9.5565 |
| 11:38 ET | 2671 | 9.56 |
| 11:39 ET | 1907 | 9.57 |
| 11:41 ET | 1745 | 9.565 |
| 11:43 ET | 2111 | 9.5262 |
| 11:45 ET | 10901 | 9.51 |
| 11:48 ET | 3493 | 9.53 |
| 11:50 ET | 4336 | 9.53 |
| 11:52 ET | 2310 | 9.53 |
| 11:54 ET | 850 | 9.5439 |
| 11:56 ET | 800 | 9.58 |
| 11:57 ET | 700 | 9.595 |
Today
Nov 4, 2024
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium, from 8:30AM ET on Monday Nov 04, 2024 by Dow Jones
8:30AM ET on Monday Nov 04, 2024 by Dow Jones
Oct 31, 2024
DJ CorMedix Is Maintained at Buy by Needham, from 6:21AM ET on Thursday Oct 31, 2024 by Dow Jones
6:21AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 30, 2024
DJ CorMedix Down Over 15%, On Pace for Largest Percent Decrease Since June 2023 -- Data Talk, from 11:56AM ET on Wednesday Oct 30, 2024 by Dow Jones
11:56AM ET on Wednesday Oct 30, 2024 by Dow Jones*DJ CorMedix 3Q Loss/Shr 5c >CRMD, from 7:30AM ET on Wednesday Oct 30, 2024 by Dow Jones
7:30AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CorMedix Inc | 604.3M | -12.0x | --- |
Zevra Therapeutics Inc | 511.6M | -4.9x | --- |
Elite Pharmaceuticals Inc | 658.9M | -104.9x | --- |
Eton Pharmaceuticals Inc | 290.1M | -57.7x | --- |
Cipla Ltd | 14.4B | 0.0x | --- |
Incannex Healthcare Inc | 34.9M | -1.4x | --- |
Company Information
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Contact Information
- Headquarters
- 300 Connell Drive, Suite 4200BERKELEY HEIGHTS, NJ, United States 07922
- Phone
- 908-517-9500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Myron Kaplan
- Chief Executive Officer, Director
- Joseph Todisco
- Chief Financial Officer, Executive Vice President
- Matthew David
- Executive Vice President, Chief Clinical Strategy and Operations Officer
- Elizabeth Massonhurlburt
- Executive Vice President, Chief Legal Officer and Corporate Secretary
- Beth Kaufman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $604.3M |
|---|---|
Revenue (TTM) | $12.3M |
Shares Outstanding | 60.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.55 |
EPS | $-0.80 |
Book Value | $1.28 |
P/E Ratio | -12.0x |
Price/Sales (TTM) | 49.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -415.59% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
